86 related articles for article (PubMed ID: 7310627)
1. [Availability of phenobarbital from suppository form (author's transl)].
Puech A; Lasserre Y; Jacob M; Duru C
J Pharm Belg; 1981; 36(5):332-6. PubMed ID: 7310627
[No Abstract] [Full Text] [Related]
2. Biopharmaceutical investigation of rectal suppositories. Part 2(1): Pharmaceutical and biological availability of phenobarbital and phenobarbital-sodium.
Minkov E; Lambov N; Kirchev D; Bantutova I; Tencheva J
Pharmazie; 1985 Apr; 40(4):257-9. PubMed ID: 3839310
[TBL] [Abstract][Full Text] [Related]
3. [Dissolution of phenobarbital from anal suppositories (investigations in vitro) (author's transl)].
Nerlo H; Kosior A
Ann Univ Mariae Curie Sklodowska Med; 1978; 33():255-9. PubMed ID: 757936
[No Abstract] [Full Text] [Related]
4. [A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)].
Maier-Lenz H; Ringwelski L; Windorfer A
Arzneimittelforschung; 1981; 31(1):105-9. PubMed ID: 7194086
[TBL] [Abstract][Full Text] [Related]
5. [Liberation of active substances from suppository bases. II. In vivo studies of phenobarbital suppositories].
Grzesiczak A; Ludwicki H; Ostrowska E
Acta Pol Pharm; 1981; 38(4):493-7. PubMed ID: 7331837
[No Abstract] [Full Text] [Related]
6. Bioavailability of phenobarbital by rectal administration.
Matsukura M; Higashi A; Ikeda T; Matsuda I
Pediatr Pharmacol (New York); 1981; 1(3):259-65. PubMed ID: 7346746
[TBL] [Abstract][Full Text] [Related]
7. Biopharmaceutical investigation of rectal suppositories. Part 3: Influence of particle size on the bioavailability of drugs.
Minkov E; Lambov N; Peneva B
Pharmazie; 1986 Jan; 41(1):63-4. PubMed ID: 3960955
[No Abstract] [Full Text] [Related]
8. [Kinetics of liberation from suppository bases of phenobarbital acid and sodium and a semi-synthetic glyceride (Witepsol H 15). II. Suppositories after storage].
Lasserre Y; Peneva MB; Jacob M; Puech A; Sabatier R
Pharm Acta Helv; 1987; 62(10-11):287-91. PubMed ID: 3438314
[No Abstract] [Full Text] [Related]
9. Bioavailability of phenobarbital from different pharmaceutical dosage forms.
Leucuta SE; Popa L; Ariesan M; Popa L; Pop RD; Kory M; Toader S
Pharm Acta Helv; 1977; 52(11):261-6. PubMed ID: 614587
[No Abstract] [Full Text] [Related]
10. [On the action of various factors on the liberation from suppositories (author's transl)].
Bornschein M; Grohmann A; Voigt R
Pharmazie; 1980 Dec; 35(12):772-6. PubMed ID: 7208579
[TBL] [Abstract][Full Text] [Related]
11. Enhanced absorption of phenobarbital from suppositories containing phenobarbital povidone coprecipitate.
Iwaoku R; Okamatsu Y; Kino S; Arimori K; Nakano M
Chem Pharm Bull (Tokyo); 1984 Mar; 32(3):1091-5. PubMed ID: 6744481
[No Abstract] [Full Text] [Related]
12. [The bioavailability of trapidil from suppositories (author's transl)].
Bornschein M; Grohmann A; Hackenberger F; Grune D
Pharmazie; 1981 Dec; 36(12):830-2. PubMed ID: 7330086
[TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of aminophylline tablet and suppository (author's transl)].
Yoshioka E; Kondo R; Kubo H; Moriguchi I; Suguro N
Yakugaku Zasshi; 1979 Sep; 99(9):895-900. PubMed ID: 547051
[No Abstract] [Full Text] [Related]
14. Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants.
Yukawa E; Suematsu F; Yukawa M; Minemoto M
J Clin Pharm Ther; 2005 Apr; 30(2):159-63. PubMed ID: 15811169
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between polymorphism and bioavailability of phenobarbital (author's transl)].
Kato Y; Watanabe F
Yakugaku Zasshi; 1978 May; 98(5):639-48. PubMed ID: 660436
[No Abstract] [Full Text] [Related]
16. [Characterization of storage-induced release reductions in suppositories (author's transl)].
Voigt R; Grohmann A; Bornschein M
Pharmazie; 1981 Sep; 36(9):631-3. PubMed ID: 7301905
[TBL] [Abstract][Full Text] [Related]
17. [Kinetics of release from suppositories formulated with phenobarbital acid or sodium, and semi-synthetic glyceride (Witepsol H 15). I. Freshly prepared suppositories].
Lasserre Y; Peneva B; Jacob M; Puech A
Pharm Acta Helv; 1984; 59(3):77-9. PubMed ID: 6718438
[No Abstract] [Full Text] [Related]
18. [Determination of an administration route for the phenobarbital in neonates suffering from neurological troubles (author's transl)].
Riche C; Bourin M; Guedes Y; Alix D; Gold F; Conan G
Therapie; 1980; 35(6):693-7. PubMed ID: 7233358
[No Abstract] [Full Text] [Related]
19. [The determination of the real dissolution rate of drug substances in melted suppository masses].
Schöbel H; Klaus T; Raguse U; Pflegel P
Pharmazie; 1988 Sep; 43(9):650-1. PubMed ID: 3244737
[No Abstract] [Full Text] [Related]
20. [Withdrawal of meprobamate and reduction of barbiturates in psychiatric patients (author's transl)].
Rebori A; Chiang N
Rev Med Chil; 1978 Jun; 106(6):420-3. PubMed ID: 715313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
